| Literature DB >> 27488523 |
Lee W Jones1, Marilyn L Kwan2, Erin Weltzien2, Sarat Chandarlapaty3, Barbara Sternfeld2, Carol Sweeney4, Philip S Bernard5, Adrienne Castillo2, Laurel A Habel2, Candyce H Kroenke2, Bryan M Langholz6, Charles P Queensberry2, Chau Dang3, Britta Weigelt3, Lawrence H Kushi2, Bette J Caan2.
Abstract
To investigate whether the impact of postdiagnosis exercise on breast cancer outcomes in women diagnosed with early-stage breast cancer differs on the basis of tumor clinicopathologic and molecular features. Using a prospective design, 6,211 patients with early-stage breast cancer from two large population-based cohort studies were studied. Age-adjusted and multivariable Cox regression models were performed to determine the relationship between exercise exposure (total MET-hours/week) and recurrence and breast cancer-related death for: (i) all patients ("unselected" cohort), and on the basis of (ii) classic clinicopathologic features, (iii) clinical subtypes, (iv) PAM50-based molecular intrinsic subtypes, and (v) individual PAM50 target genes. After a median follow-up of 7.2 years, in the unselected cohort (n = 6,211) increasing exercise exposure was not associated with a reduction in the risk of recurrence (adjusted Ptrend = 0.60) or breast cancer-related death (adjusted Ptrend = 0.39). On the basis of clinicopathologic features, an exercise-associated reduction in breast cancer-related death was apparent for tumors <2 cm [HR, 0.50; 95% confidence interval (CI), 0.34-0.72], well/moderately differentiated tumors (HR, 0.63; 95% CI, 0.43-0.91), and ER-positive tumors (HR, 0.72; 95% CI, 0.53-0.97). Stratification by clinical subtype indicated that the ER(+)/PR(+)/HER2(-)/low-grade clinical subtype was preferentially responsive to exercise (recurrence: adjusted HR, 0.63; 95% CI, 0.45-0.88; breast cancer-related death: adjusted HR, 0.57; 95% CI, 0.37-0.86). The impact of exercise on cancer outcomes appears to differ as a function of pathologic and molecular features in early-stage breast cancer. Cancer Res; 76(18); 5415-22. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Year: 2016 PMID: 27488523 PMCID: PMC5026589 DOI: 10.1158/0008-5472.CAN-15-3307
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701